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Abstract
Despite being caused by a single protein, prion diseases are
strikingly heterogenous. Individual prion variants, known as
strains, possess distinct biochemical properties, form aggre-
gates with characteristic morphologies and preferentially seed
certain brain regions, causing markedly different disease
phenotypes. Strain diversity is determined by protein structure,
post-translational modifications and the presence of extracel-
lular matrix components, with single amino acid substitutions
or altered protein glycosylation exerting dramatic effects. Here,
we review recent advances in the study of prion strains and
discuss how a deeper knowledge of the molecular origins of
strain heterogeneity is providing a foundation for the develop-
ment of anti-prion therapeutics.
Addresses
Institute of Neuropathology, University Hospital of Zurich, University of
Zurich, Schmelzbergstrasse 12, 8091 Zurich, Switzerland
Corresponding author: Aguzzi, Adriano (adriano.aguzzi@usz.ch)
Current Opinion in Neurobiology 2022, 72:22–31
This review comes from a themed issue on Neurobiology of Disease
Edited by Bart de Strooper and Huda Zoghbi
For a complete overview see the Issue and the Editorial
Available online 27 July 2021
https://doi.org/10.1016/j.conb.2021.07.010
0959-4388/© 2021 The Author(s). Published by Elsevier Ltd. This is an
open access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).
Introduction
Prion diseases are a group of fatal neurodegenerative
disorders caused by prions. These unique infectious
agents are not known to contain any nucleic acids and
appear to be composed primarily of a misfolded form of
the prion protein PrP, which is encoded by the prion
protein gene PRNP [1,2]. Histologically, prion diseases
show vacuolation, astrogliosis, neuroinflammation and
deposition of PrPSc, a misfolded, beta-sheeterich
counterpart of the cellular prion protein PrPC, a
glycosylphosphatidylinositol-anchored (GPI-anchored)
protein that is abundantly expressed in the brain. Prions
propagate through the templated misfolding of PrPC to
infectious prion aggregates [3].
Most cases of human prion disease are sporadic (spo-
radic CreutzfeldteJakob disease, sCJD), with no known
cause. Inherited PRNP mutations cause the genetic
prion diseases familial CreutzfeldteJakob disease,
GerstmanneSträusslereScheinker syndrome (GSS) and
fatal familial insomnia. Prion diseases acquired via
infection include variant CJD and kuru, where prions are
acquired via dietary routes, and iatrogenic CJD, caused
by accidental inoculation through medical procedures
[4].
Although they are caused by a misfolded form of one
single protein, prion diseases of animals and humans are
strikingly heterogenous and are associated with a wide
range of clinicopathological variants with different
symptoms, incubation periods, rates of disease progres-
sion, histology, PrPSc deposit morphologies and
anatomical distributions of disease lesions [5e7].
Given that prions are not known to contain nucleic
acids, these properties must be encoded in the higher-
order aggregate structure. Indeed, prions exist in
distinct conformational variants, known as strains, whose
properties can be serially transmitted and reproduced in
animal models of disease and also in human infection
[6,8,9]. Furthermore, human sporadic prion disease
strains can also be reproduced by the in vitro prion
amplification technique protein misfolding cyclic
amplification (PMCA), where prions are propagated in
the presence of brain homogenate [10].
Individual prion strains produce PrPSc with distinct
biochemical properties, such as the degree of electro-
phoretic mobility [11], susceptibility to protease
digestion, immunoreactivity to antibodies targeting
conformational PrP epitopes [12], glycosylation patterns
[13] and stability on treatment with chaotropic salts
[14] or heat [15].
Prion strains cause pathology with specific anatomical
distributions. A study of sCJD with diffusion-weighted
magnetic resonance imaging showed that the disease
primary site and ordering of lesion propagation were
specific to sCJD histotypes, which are caused by distinct
strains. For instance, in the most common histotype,
MM1, lesions spread from the neocortex to subcortical
regions, with the opposite pattern seen in the histotype
VV2 (see Figure 1) [16**]. The observation that many
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self-templating prion strains with defined properties
exist leads to the question of how their structure was
formed in the original prion seed and how the strain-
coding information is transmitted during prion replica-
tion. Here, we review how recent histological, genetic
and biochemical studies are unravelling the molecular
origins of prion strain diversity and discuss how these
advances are guiding the development of innovative
anti-prion therapeutics.
Determinants of strain properties
Prion protein primary structure
The properties of de novo prion seeds are influenced by
the primary amino acid sequence of PrP. For instance, a
geographically variable polymorphism in codon 129 of
PRNP, which codes for methionine (M) or valine (V),
influences biochemical features of prions when they
emerge in the primary host, and these properties can be
transmitted with infection [17e19]. This polymorphism
also influences the risk of spontaneously developing
prion disease [20], age at onset of genetic disease
[21,22], clinical and histological features of disease [7]
and the incubation period after exposure to prions [23].
In line with the last observation, the overall PrP
sequence determines species barriers; while bank voles
can be readily infected with strains originating in various
species and bank vole PrP is susceptible to conversion by
several human prion strains [24,25], dogs are resistant to
prion infection, probably thanks to the presence of a
single negatively charged amino acid (aspartic or gluta-
mic acid) in position 163 of canine PrP, a residue not
found in other species [26]. Mutations that alter the
amino acid sequence of PrP can cause hereditary prion
disease. Around 50e60 variants have been described,
including missense mutations, truncations [27] and in-
sertions into the octapeptide repeat region of PrP
[28,29], a repetitive domain close to the PrP N-terminus
likely to be a mediator of prion toxicity [30]. Full
penetrance has been established for four missense mu-
tations, which also demonstrably cause the formation of
infectious prions, as shown by transmissibility experi-
ments where rodents and non-human primates were
inoculated with material obtained from diseased brains
of mutation carriers; furthermore, in mice, homologous
Prnp mutations cause spontaneous disease [31e34].
Individuals with sporadic prion disease are not known to
carry any of these pathogenic mutations in the germline.
PRNP polymorphisms can also be protective. A study of
persons who were exposed to kuru via cannibalistic
funerary practices, but did not develop the disease, lead
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Prion strains cause different disease phenotypes. PrPsc aggregate morphology and anatomical spreading patterns (based on the study by Pascuzzo
et al. [16**]) are shown in the CJD histotypes MM1 and VV2. MM1 is the main CJD subtype found in individuals homozygous for methionine at PRNP
codon 129, whereas VV2 is the main type in valine homozygous individuals. Dark colour indicates the ‘epicentre’ of pathology, with lighter coloured
regions affected later in the disease course. (a) Small punctate synaptic PrPsc deposits in MM1, cerebellar cortex. (b) Plaque-like PrPsc deposits in VV2,
cerebellar cortex. (c) In MM1, diffusion-weighted imaging showed that pathology most often began in the precuneus and parietal lobe, followed by spread
to the frontal and cingulate lobes, with the cerebellum and thalamus affected at late stages. (d) In VV2, the cerebellum is usually affected early in the
disease, followed by spread to the basal ganglia and thalamus, insular cortex, frontal lobe and parietal lobe, with the occipital cortex affected at a late
stage.
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emergence was favoured by the selective pressure of the
kuru epidemic [35]. Overall, these observations high-
light how substituting a single amino acid in PrP can
drastically influence the formation and propagation of
prion disease, with effects ranging from protective to
inexorably fatal. Several genome-wide association
studies have attempted to find variants in other genes
that influence the risk of developing prion disease, but
the rarity of prion disease poses a significant challenge to
these efforts. Apart from variants in PRNP, the search for
associations has been mostly elusive, but weak associa-
tions with variants in STX6 and GAL3ST1 were reported
recently. Risk single nucleotide polymorphisms (SNPs)
in STX6 are also shared with progressive supranuclear
palsy, possibly indicative of common causal mechanisms
[36**].
Aggregate biophysics
The pathogenicity of prions is associated with certain
biophysical properties which lead to the formation of
aggregates with characteristic morphologies. Mouse-
adapted prions that form smaller, diffuse, subfibrillar
aggregates and are unstable under denaturing conditions
are particularly pathogenic and more likely to enter the
central nervous system through peripheral nerves,
whereas plaque-forming prions are likely to be less
pathogenic [37]. Indeed, although both subfibrillar and
fibrillar strains can be taken up by neurons by macro-
pinocytosis and transported through axons to the cell
body, only subfibrillar strains were efficiently trans-
ported to the brain. Sonicating fibrillar strains signifi-
cantly increased solubility and disease attack rate on
peripheral inoculation, showing that smaller PrP species
are more pathogenic and that promoting fibril stability
and assembly could slow prion propagation [38]. This
makes sense mechanistically because the prion is
defined as the minimal infectious unit, and it logically
consists of one single molecular aggregatedwhatever its
size. Hence, taking a fibril and fragmenting it into a large
number of smaller aggregates is necessarily bound to
increase the number of infectious particles even if the
total amount of prion protein remains unchanged. In
humans, small, non-fibrillar prions are also likely to be
particularly infectious. Purified protease-resistant GSS
aggregates containing PrP amino acids ~90e150 were
highly infectious and capable of causing disease on their
own, suggesting that this part of the protein is a minimal
component required for prion formation [39*].
A potentially protective prion strain has also been
described. Anti-prions are self-replicating but innocuous
PrP aggregates which can compete with toxic prions for
their substrate PrPC, resulting in its depletion, inhibit-
ing the spread of toxic prions. When given as a prophy-
lactic treatment in hamsters, anti-prions significantly
delayed the onset of clinical symptoms after inoculation
with a highly pathogenic prion strain. These findings
indicate that prion replication and toxicity are uncou-
pled and provide a remarkable example of the pheno-
typic diversity of prion strains [40**].
Cofactors of prion replication
Prions typically form diffuse, synaptic or punctate de-
posits, whereas the formation of amyloid plaques
composed of PrP is relatively rare and typically associ-
ated with a longer disease duration; however, certain
strains preferentially form plaques when inoculated into
wild-type mice [41*]. Therefore, genetic modifications
that alter the pattern of prion deposition could be of
particular interest. Whether prion strains form diffuse
deposits or plaques has been proposed to be influenced
by cofactors, particularly by glycosyl residues of PrP,
phospholipids and polyanionic compounds such as RNA
or extracellular matrix (ECM) components [42]. In
particular, glycans stabilise PrP and can inhibit fibril
nucleation [43,44].
A recent study explored the effect of the ECM
component heparan sulphate (HS) by inoculating prions
into mice which produce shortened HS chains.
Prolonged survival and redistribution of PrP plaques
from brain parenchyma to blood vessels were seen after
infection with fibrillar, plaque-forming prions. Plaques
consisted of extracellularly assembled, protease-cleaved,
GPI-anchorless PrP and were also enriched in HS.
Similarly, in sCJD and GSS, plaque-forming prions had
the highest amounts of bound HS, whereas lower levels
were seen in cases with diffuse deposits. Given that HS
deficiency prolonged survival, HS was found to be a
disease-modifying cofactor of prion replication that ac-
celerates prion disease progression [45*].
A similar study investigated the significance of PrP
glycosylation using 1. subfibrillar prions, 2. plaque-
forming prions and 3. prions consisting of GPI-
anchored PrP, which were inoculated into mice with
different PrP glycosylation profiles. Expression of
underglycosylated PrP resulted in prions that are usually
subfibrillar forming plaques, which consisted of PrP
cleaved by the protease ADAM10 and HS. The opposite
effect was seen in mice producing triglycosylated PrP:
here, challenge with plaque-forming prions leads to
accelerated disease with deposition of diffuse, subfi-
brillar aggregates. GPI-anchored prions recruited
unglycosylated, GPI-anchored PrP and aggregated to
large plaques. However, no difference was seen after
infection with the third strain consisting of unmodified,
GPI-anchored PrP, which formed diffuse, HS-deficient
deposits irrespective of altered glycosylation. These
findings highlight how glycans, protease cleavage and
GPI anchors shape prion disease phenotypes, with a
strong influence on aggregate morphology, disease pro-
gression and interaction with polyanionic HS being
evident. In particular, PrP plaques appeared to be
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preferentially formed by underglycosylated PrP, whereas
addition of glycosyl residues favoured the deposition of
subfibrillar aggregates [41*].
In another study investigating the influence of cofactors
on pathogenicity, a protein-only PrPSc preparation pro-
duced from recombinant PrP by the prion-amplification
technique PMCA failed to induce disease after inocu-
lation into bank voles, which are highly susceptible to
infection by various prion strains. However, if the same
protein-only PrPSc was seeded into a PMCA reaction
containing brain homogenate, potently infectious PrPSc
was produced, indicating that native PrP (not recombi-
nant PrP produced in bacteria) and additional cofactors
present within brain homogenate were required for
in vitro production of highly pathogenic prions [46].
Using PMCA, it was also found that prion strains repli-
cated preferentially in the presence of PrP glycoforms
and cofactor molecules that were found in the host
species where the prions originated. Given that PrP
expression, PrP glycosylation [47], membrane lipids and
ECM components vary throughout the brain, strain-
specific patterns of neurotropism probably depend on
the presence of PrP glycoforms and cofactor molecules
in different parts of the brain, that is, prions preferen-
tially propagate in brain regions that provide the sub-
strates required by an individual prion strain for efficient
conversion [48*].
Antemortem diagnosis of sCJD is now commonly made
with real-time quaking-induced conversion (RT-QuIC)
assays, which can detect prions in patients’ cerebrospi-
nal fluid with very high sensitivity [49,50]. In RT-QuIC
assays, the presence of PrPSc in the analyte provokes
misfolding of PrPC through cycles of elongation and
fragmentation, generating aggregates that can be stained
with the fluorescent dye thioflavin T. It is important to
understand that the original intuition of breaking ag-
gregates and letting them regrow cyclically, which was
implemented in PMCA, predates RT-QuIC by more
than a decade. It was Claudio Soto who demonstrated,
in a landmark experiment, that this was possible [24].
While RT-QuIC improved technically on the Soto
methodology by substituting sonication with quaking, it
was an evolutionary refinement rather than a revolu-
tionary invention. As mentioned, PMCA products are
demonstrably infectious. To investigate whether RT-
QuIC products are pathogenic prions or an innocuous
form of aggregated PrP, RT-QuIC products were inocu-
lated into the brains of mice overexpressing human PrP,
where they failed to induce clinically apparent disease.
However, histological workup of the inoculated brains
revealed the presence of abnormal cortical PrP deposits
and vacuolation, but no evidence of gliosis was found.
RT-QuIC seeding activity was also detected in the
inoculated brains. These results indicate that RT-QuIC
products can provoke PrP aggregation and limited
cellular pathology in vivo but that they represent a
species of PrP that is distinct from pathogenic prions
[51*]. Nevertheless, the finding that a limited degree of
pathology was present is of note and provides further
evidence that PrP aggregates encompass a spectrum of
many different species, whose degree of pathogenicity
ranges from innocuous to highly infectious.
Taken together, these studies of PrP post-translational
modification provide compelling evidence for a critical
role of PrP glycosylation and of cofactors found in brain
homogenate (possibly lipids and ECM components such
as HS) in prion propagation, particularly in the forma-
tion of infectious aggregates. Furthermore, the spatial
distribution of PrP post-translational modifications and
of cofactor molecules in the brain might explain why
individual strains preferentially seed pathology in
certain brain regions.
Structural and biophysical studies
Recent studies have provided unprecedented insight
into the molecular structure of prion fibrils. Using cryo-
electron microscopy, a denaturant- and protease-
resistant prion fibril formed from an unglycosylated
fragment of human PrP was shown to contain two
intertwined protofilaments with screw symmetry linked
by a hydrophobic interface. Based on this structure,
certain familial prion disease variants were predicted to
form closely related polymorphs and a protective amino
acid substitution was predicted to form steric clashes,
explaining why it might disrupt prion fibril formation
[52**]. A similar structural study in preprint of scrapie
prions carrying post-translational modifications demon-
strated how glycosyl residues markedly alter fibril
structure. Moreover, GPI anchors might cause fibrile
membrane interactions that are likely to be highly
relevant to prion propagation and pathology [53]. The
findings in these structural studies could help explain
how prion strain properties are shaped by the PrP amino
acid sequence and post-translational modifications,
providing a molecular basis for strain diversity.
Novel biophysical and microfluidic diffusional sizing
methods have enabled the study of prion propagation
kinetics both in vitro and in vivo. In a recent study, such
methods were used to formulate a mathematical
framework of prion aggregation kinetics. In vivo prion
aggregation kinetics of prions were consistent with
in vitro findings and demonstrated that fragmentation
was the dominant mode of prion fibril replication in vivo
[54*].
Novel approaches to prion genetics
Somatic mutations
The rarity of sporadic prion disease renders it very
challenging to use population genetics to uncover novel
risk loci. Alternative approaches are therefore needed.
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In recent years, several remarkable studies have shown
how the human brain is a genomic mosaic, with indi-
vidual cells harbouring clonal or private mutations that
were acquired as a consequence of mutagenic processes,
some of them potentially altering the function of
affected genes [55,56]. This genomic diversity raises
the possibility that somatic mutations in key disease-
related genes could contribute to neurodegeneration,
including to the pathogenesis of prion disease, and
several recent studies have begun to investigate this
possibility.
With ageing and in Alzheimer’s disease, a number of
putatively pathogenic mutations were detected in
pathways implicated in hyperphosphorylation of tau,
suggesting that they might have contributed to
Alzheimer’s disease pathology [57*]. A similar study of
semantic dementia revealed individuals with putatively
pathogenic mosaic mutations in TARDBP (with a
mutant allele fraction of 1e3%), one of the main genes
implicated in the pathogenesis of this neurodegenera-
tive disease [58]. A study of the synucleinopathies
Parkinson’s disease and multiple system atrophy found
that nigral dopaminergic neurons harboured somatic
SNCA (a-synuclein) copy number gains compared with
controls, suggesting that supernumerary SNCA copies,
possibly leading to overexpression of a-synuclein, might
be a significant pathogenetic risk factor [59]. Indeed,
germline locus triplication of SNCA is a long-known
cause of hereditary Parkinson’s disease [60].
Somatic mutations were already proposed to lie at the
origin of sporadic prion disease around 30 years ago [61],
but there are no reports on large-scale searches for
PRNP mutations in prion disease samples. Although
biosafety hazards and the limited availability of patient
samples render it difficult to sequence DNA from the
prion-contaminated brain, targeted sequencing of PRNP
or whole genome sequencing of the somatic genome
could potentially uncover known pathogenic variants or
novel genetic risk factors.
Screens
Genetic screens might also identify crucial genes hith-
erto undetected by population genetics. An arrayed
whole-transcriptome RNA interference screen in pre-
print identified a number of genes regulating PrPC
biosynthesis, with the RNA-binding post-transcriptional
repressor Pumilio-1 emerging as a potent regulator
causing degradation of PRNP mRNA [62]. Similar
screens for genes regulating prion propagation or pro-
duction of potential prion co-factors could help unravel
prion pathogenesis and disease heterogeneity. The ‘hits’
uncovered by such unbiased screens could represent
genetic risk loci for sporadic prion disease, potentially
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Mechanisms of action of anti-prion therapeutics. RNA coding for PrP is translated, forming PrPC (blue molecules). At the onset of prion pathology,
PrPC forms a primary prion seed composed of misfolded monomers (red blocks). Aggregates grow by recruiting and misfolding further PrPC monomers.
Prion aggregates fragment (lightning) into smaller daughter prions, which continue to replicate by a cycle of elongation and fragmentation. Prions interact
with cell surface PrPC, initiating toxic signalling pathways. Antisense oligonucleotides bind RNA and cause it to be degraded, inhibiting expression of
PrPC. Anti-prions are non-toxic prion strains which deplete PrPC, preventing its recruitment into toxic prions. Therapeutic antibodies bind PrPC, with
several beneficial effects: prevention of prions from binding PrPC, decreased protein misfolding and inhibition of toxic signalling. Therapeutic antibodies
and luminescent conjugated polythiophenes (LCPs) stabilise aggregates, preventing fragmentation into daughter prions.
26 Neurobiology of Disease
Current Opinion in Neurobiology 2022, 72:22–31 www.sciencedirect.com
patients. In a different screen using a short-hairpin
RNA library targeting 133 genes related to protein ho-
meostasis, several members of the Hsp70 family of
chaperones and related proteins were identified as reg-
ulators of PrPC expression. A molecule inhibiting the
Hsp70 family reduced PrPC levels and also PrPSc for-
mation [63]. Although this finding could hold promise
for the development of small-molecule therapeutics, it
might be necessary to find a more specific Hsp70 family
member that is of relevance to prion pathophysiology, as
the pervasive functions of the Hsp70 family in cell
biology might make them too broad a target [64].
Therapies
Next, we discuss how recent findings in the field of
prion research could inform the development of anti-
prion therapeutics (see the overview in Figure 2).
Aggregate stabilisation
Given that prions replicate via fragmentation, stabilisa-
tion of aggregates with molecules that intercalate into
the quaternary structure of prions could be a promising
therapeutic strategy. Luminescent conjugated polymers
bind prions and other amyloids [6,65], stabilise prions
[66] and extend the lifespan of prion-infected mice by
up to 80%, while being well-tolerated [67]. Given that
these molecules are luminescent, imaging approaches
could be used to track their function and distribution
in vivo. Using similar compounds and multiphoton mi-
croscopy, longitudinal imaging of the spread of tau and
amyloid was achieved in vivo [68**]. Similar studies of
prions, with longitudinal imaging surveillance of their
effects, might help identify promising drug candidates.
Polymers that specifically bind prion aggregates could
also be conjugated to effector molecules, such as
immunological signalling proteins, for specific targeting
of aggregates.
Antibodies
Anti-PrP antibodies exert differential effects depending
on their targeted epitope. Antibodies binding the C-
terminal globular domain of PrP are toxic and reproduce
many of the features of prion disease, whereas anti-
bodies binding the N-terminal flexible tail protect
against disease, presumably by preventing prions from
binding PrPC and exerting toxic effects [30]. Recent
data from our laboratory show that expression of PrPC in
neuronsdbut not astrocytesdis required for prion
toxicity [69]; hence, preventing prions from binding
neuronal PrPC with suitable antibodies might be a viable
strategy to prevent neurodegeneration.
Anti-PrP autoantibodies, including clones with thera-
peutic potential, were recently shown to be found in
healthy individuals. No associations with manifest prion
disease, PRNP mutation status or any other specific
pathologies could be identified, indicating that
circulating anti-PrP antibodies are likely to be well-
tolerated, making them a viable therapeutic approach
[70,71]. Rationally designed therapeutic anti-PrP anti-
bodies have already shown promise in early experi-
mental studies. A bispecific antibody which
simultaneously targets both the globular and flexible tail
domains of PrP reduced neurotoxicity and the formation
of soluble oligomers in a brain slice model of prion dis-
ease, possibly by blocking the prion-binding site in the
globular domain and stabilising the flexible tail [72].
Further studies, particularly in vivo treatments, are
required to determine whether anti-PrP antibodies
might hold promise as a neuroprotective therapy or
possibly also as promoters of prion clearance. In partic-
ular, whether limited passage through the bloodebrain
barrier could be a hindrance to therapy remains to be
elucidated.
Antisense oligonucleotides
Gene knockout of mouse Prnp produces a demyelinating
polyneuropathy phenotype, as PrP is required for myelin
maintenance in peripheral nerves [73,74], but in the
central nervous system, lack of PrP expression is
currently not known to produce significant effects.
Consequently, depleting PrP in the brain might be a
promising therapeutic strategy to treat prion disease or a
prophylactic strategy to prevent PRNP mutations from
causing outbreak of genetic prion disease (as in the anti-
prion approach described previously). A promising
strategy to reduce PrP expression is knockdown using
antisense oligonucleotides (ASOs), single-stranded
DNA fragments that specifically bind their target
mRNA, leading to its degradation by RNase H1. Chronic
suppression of PrP expression with ASO treatment
extended survival of prion-infected mice in both pro-
phylactic and therapeutic settings, even if given shortly
before the onset of evident neuropathology [75**].
In a follow-up study, ASO treatment conferred robust
dose-dependent benefits in mice infected with 5
different prion strains, with 21% RNA knockdown
already extending survival. ASOs even extended sur-
vival if given after the onset of clinically evident dis-
ease, in which case they attenuated symptoms and
lowered concentrations of biomarkers of neuronal injury
[76]. Given that ASOs act by depleting the substrate of
prion conversion, their action is independent of strain
properties, meaning that they could be effective in all
forms of prion disease. This is in contrast to stabilising
agents such as luminescent conjugated polymers, which
would probably only be effective against certain strains.
Furthermore, ASOs could potentially be designed to
specifically knock down mutant variants of PRNP and
be used as a prophylactic treatment of PRNP mutation
carriers, which might delay or even prevent the
outbreak of disease. Combination therapies with ASOs
and stabilising agents or antibodies might be
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particularly promising. Stabilising agents would confer
the additional benefit of inhibiting prion fragmentation,
whereas antibodies might enhance prion clearance or
prevent the toxic cascade initiated by prions on binding
of PrPC. Overall, combination therapies might give
microglia time to clear prions, significantly prolonging
survival.
Conclusion
The observation that prion strains composed of a single
protein are capable of causing a diverse range of patho-
logical phenotypes has baffled scientists for many de-
cades. Recent advances have brought unprecedented
insight into the genetic and biochemical phenomena
that shape prion strain diversity. Even though prions are
believed to principally consist of protein, the role of
non-protein cofactors such as glycans, polyanionic mac-
romolecules and GPI anchors in prion propagation is
becoming increasingly apparent. Furthermore, structural
studies are elucidating the influence of mutations and
post-translational modifications on the molecular archi-
tecture of prions. Although prion propagation is
increasingly understooddwith aggregate fragmentation
being shown to play a critical roledhow prions begin
their existence in the first place is still shrouded in
mystery. Here, emerging fields such as the study of
genomic heterogeneity and high-content genetic
screens might provide further insight into the origin and
propagation of prions. A deeper understanding of prion
diversity is also likely to inform design of specific anti-
prion therapeutics, with approaches that stabilise ag-
gregates, target critical prion epitopes or deplete prion
protein holding particular promise.
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